Key result
Acarbose significantly attenuated hyperglycemia (p<0.01) and reduced rises in insulin and enteroglycagon (p<0.05) in dumping syndrome, though long-term symptom reduction was not significant.
Why the study?
Does acarbose improve biochemical responses and clinical symptoms in patients with dumping syndrome?
Does acarbose improve biochemical responses and clinical symptoms in patients with dumping syndrome?
p-value: p=<0.01
Acarbose improves biochemical markers associated with dumping syndrome but does not yield a statistically significant reduction in clinical symptoms over a 1-month period.
Acarbose improves biochemical responses in dumping syndrome without significant symptom benefit; leaves open clinical utility pending RCTs.
A dose of 50 mg of acarbose was administered with a standard breakfast to 13 subjects with dumping syndrome. Significant attenuation of hyperglycaemia (p less than 0.01) was observed, and rises in plasma gastric inhibitory polypeptide, insulin and enteroglycagon were reduced (p less than 0.05). Plasma levels of neurotensin, vasoactive intestinal polypeptide and somatostatin were not affected. Dumping score was reduced, but this did not achieve statistical significance. In a longer-term study, 9 patients took acarbose, 50 mg t.i.d., for 1 month. No significant reduction in the number or severity of dumping attacks was observed, but a majority expressed a preference for the drug and some individuals experienced a marked improvement of symptoms.
No takes yet. Share an insight, caveat, or question.
Lyons et al. (2009) studied Dumping syndrome (n=13). Acarbose was evaluated on Hyperglycaemia and hormone levels (gastric inhibitory polypeptide, insulin, enteroglycagon) (p=<0.01). Acarbose significantly attenuated hyperglycemia (p<0.01) and reduced rises in insulin and enteroglycagon (p<0.05) in dumping syndrome, though long-term symptom reduction was not significant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: